Susceptibility profile of methicillin-resistant Staphylococcus aureus to linezolid in clinical isolates

Ali Shariq; Syed Bilal Tanvir; Atif Zaman; Salman Khan; Armeena Anis; Misha Aftab Khan; Sumaira Ahmed

View/Download PDF

Buy Reprints

PDF

Translate this page into:

Original Article

11 (

); 9-12

Susceptibility profile of methicillin-resistant Staphylococcus aureus to linezolid in clinical isolates

Ali Shariq, Syed Bilal Tanvir, Atif Zaman, Salman Khan, Armeena Anis, Misha Aftab Khan, Sumaira Ahmed

Received: 2016-01-25, Accepted: 2016-05-22, Published: 2017-02-06

Licence

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Disclaimer:
This article was originally published by Qassim University and was migrated to Scientific Scholar after the change of Publisher.

Abstract

Objective: To determine the resistance and sensitivity pattern of Methicillin-Resistant Staphylococcus aureus (MRSA) isolates to Linezolid along with its prevalence in a tertiary care hospital of Karachi, Pakistan Methods and Materials: A Cross sectional study was carried out. This study lasted for about 1 year. Prevalence and sensitivity of linezolid, Vancomycin and Oxacillin was tested against isolates of MRSA. Results: Out of total 369 specimens 165 were found to be MRSA making the prevalence in our study 44.7% .All of the isolates which were tested positive for MRSA were susceptible to linezolid and no resistance was noted when compared with previous studies performed in Europe and USA. Conclusion: Stringent implementation of infection control measures along with screening for resistance in patients on prolonged Linezolid therapy or who previously went under linezolid therapy should be performed, coupled with judicious usage of the aforementioned antibiotic should be undertaken, as sufficient data is not available at this point for the clinical spectrum of Linezolid resistant Staphylococcus aureus (LRSA), antimicrobial resistance.